Back to Ovarian Cancer
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT01178411

NCT01178411
Completed Phase 2

Who may be able to join

Who might be able to join this trial:

  • You have signed a consent form agreeing to take part in this clinical study of tivantinib (the study drug)
  • You are the age specified in the original study you were enrolled in
  • You are well enough to carry out some daily activities, based on a standard health scale used by doctors (confirm with trial site for your specific situation)
  • Your blood counts are at an acceptable level — specifically, your infection-fighting cells and red blood cells must meet certain minimum levels (confirm exact values with trial site)
  • You are enrolling within 14 days of finishing your last visit in the original study
  • You took part in a previous study of this drug (ARQ 197), that study has ended, you did not have to stop the treatment early for any required reason, and your doctor and the study team believe you may benefit from continuing treatment
  • Women who could become pregnant must have a negative pregnancy test within 14 days of starting the study drug, and both men and women must agree to use reliable birth control throughout the study

Who may not be able to join:

  • You have a known or suspected allergy to tivantinib (also called ARQ 197)
  • You have substance abuse issues, or mental, emotional, or social circumstances that could affect your ability to take part in or complete the study
  • You have any unstable health condition that could put your safety at risk or affect your ability to follow the study requirements
  • You have a serious uncontrolled medical condition that your doctor believes would prevent you from receiving the study treatment
  • You need to receive other cancer treatments at the same time, such as chemotherapy, immunotherapy, or another experimental drug — though limited radiation therapy to manage symptoms may be allowed under certain conditions (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 2
Sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Registry
clinicaltrials_gov
Start date
31 August 2010
Est. completion
14 January 2019

Primary endpoints

Extent of Exposure to ARQ 197 in Participants Benefiting From Prior ARQ 197 Therapy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov